Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NPS PHARMACEUTICALS INC (NPSP)
|
Add to portfolio |
|
|
|
| Price: |
$7.28
| | Metrics |
| OS: |
108.6
|
M
| |
-7
|
% ROE
|
| Market cap: |
$790
|
M
| |
3
|
% ROIC
|
|
Net cash:
|
$304
|
M
| |
$2.80
|
per share
|
|
EV:
|
$487
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$8.4
|
M
| |
58.0
|
x EV/EBITDA
|
|
EBIT
|
$5.1
|
M
| |
96.4
|
x EV/EBIT
|
| EPS |
($0.08)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 |
| Revenues | 224.1 | 155.6 | 130.6 | 101.6 | 89.4 | 84.1 | 102.3 | 86.2 |
| Revenue growth | 44.0% | 19.1% | 28.5% | 13.7% | 6.3% | -17.7% | 18.6% | 77.8% |
| Cost of goods sold | 14.6 | 3.6 | 0.0 | 2.5 | 0.1 | 0.5 | 12.8 | 12.4 |
| Gross profit | 209.4 | 152.0 | 130.6 | 99.1 | 89.3 | 83.7 | 89.4 | 73.9 |
| Gross margin | 93.5% | 97.7% | 100.0% | 97.5% | 99.9% | 99.4% | 87.4% | 85.6% |
| Selling, general and administrative | 114.3 | 68.1 | 36.9 | 24.2 | | | | 29.5 |
| Research and development | 90.1 | 85.4 | 94.8 | 73.8 | 60.8 | 35.3 | 19.0 | 36.2 |
| General and administrative | | | | | 19.0 | 20.1 | 22.6 | |
| EBIT | 5.1 | -1.5 | -1.1 | 0.5 | 9.6 | 27.7 | 48.3 | 52.7 |
| EBIT margin | 2.3% | -1.0% | -0.9% | 0.5% | 10.7% | 32.9% | 47.2% | 61.1% |
| Pre-tax income | -7.9 | -13.3 | -18.7 | -36.2 | -30.4 | -19.6 | -31.9 | -3.5 |
| Income taxes | 0.8 | 0.2 | 0.0 | 0.0 | 1.1 | -1.7 | -0.2 | 0.8 |
| Tax rate | | | 0.0% | | | 8.9% | 0.6% | |
| Net income | -8.7 | -13.5 | -18.7 | -36.3 | -31.4 | -17.9 | -31.7 | -4.3 |
| Net margin | -3.9% | -8.7% | -14.3% | -35.7% | -35.2% | -21.2% | -31.0% | -5.0% |
| |
| Diluted EPS | ($0.08) | ($0.14) | ($0.22) | ($0.45) | ($0.54) | ($0.37) | ($0.67) | ($0.09) |
| Shares outstanding (diluted) | 106.3 | 97.8 | 87.0 | 81.3 | 58.2 | 48.3 | 47.7 | 46.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|